Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diabetes (T2D) and baseline HbA1c (≥7.5% and ≤11%) above the German recommended HbA1c treatment target range